Biopharma AI
ByCan Bristol Myers Squibb’s $330 Million AI Investment in 2025 — Powered by Strategic Partnerships — Accelerate Discovery, R&D and Commercial Impact in 2026?
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025 — Backed by Strategic Collaborations — Accelerate Discovery, R&D and Commercial Growth in 2026?
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Can AstraZeneca’s $390 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — AstraZeneca plc significantly expanded its commitment to artificial intelligence (AI) throughout 2025,…
Can Merck’s $300 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Innovation, R&D and Commercial Success in 2026?
Global – December 31, 2025 — Merck & Co., Inc. significantly expanded its commitment to artificial intelligence (AI)…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
